STOCK WATCH
DRUGS company Clinigen is on track to toast another year of growth after a surge in first-half sales.
The pharmaceutical firm, which supplies unlicensed drugs to patients in critical need, saw a 28pc rise in the six months to December 31. Profits rose 10pc.
The boost was due to the strong performance of its commercial business and the two-month inclusion of Quantum Pharma, which it acquired in September. Shares fell 3pc, or 31p, to 1003p.